Incycus Therapeutics Appoints Melissa Beelen as Vice President, Clinical Operations
03 avr. 2019 08h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Announces FDA Approval of IND Application for a Novel Gamma-Delta (γδ) T Cell Therapy for Treatment of Patients With Newly-Diagnosed Glioblastoma
01 avr. 2019 08h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
CCAB announces creation of new brain cancer therapeutic company, Empirica Therapeutics, as part of its strategy to advance new early-stage life sciences companies
20 févr. 2019 10h30 HE
|
Centre for the Commercialization of Antibodies and Biologics
TORONTO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- The Centre for the Commercialization of Antibodies and Biologics (CCAB) today announced a license agreement with Empirica Therapeutics Inc. aimed at...
VBI Vaccines Announces Third Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent GBM Patients
07 févr. 2019 08h00 HE
|
VBI Vaccines, Inc.
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of the study without modificationEnrollment is complete in the high-dose study arm of Part AExpanded immunologic...
National Brain Tumor Society Invests in GBM AGILE, the World’s First Global Adaptive Trial for Glioblastoma Brain Cancer
16 janv. 2019 13h56 HE
|
National Brain Tumor Society
Boston, MA, Jan. 16, 2019 (GLOBE NEWSWIRE) -- National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community in the United States, today announced a partnership...
Incysus Therapeutics Completes Series A Financing and Announces the Appointment of Travis Whitfill, MPH to Its Board of Directors
03 janv. 2019 14h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Gamma-Delta (γδ) T Cell Therapy Combined With Checkpoint Inhibition Shows Potential Synergies in Vitro for Treatment of Glioblastoma
15 nov. 2018 07h00 HE
|
Incysus Therapeutics, Inc.
Promising data from gamma-delta (γδ) T cell therapy in combination with checkpoint inhibitors to be presented at 2018 Society for Neuro-Oncology annual meeting NEW YORK, Nov. 15, 2018 (GLOBE...
Oblato acquires all rights to glioblastoma drug from OMRF
29 oct. 2018 11h21 HE
|
Oklahoma Medical Research Foundation
OKLAHOMA CITY, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Oblato, Inc., has acquired all rights from the Oklahoma Medical Research Foundation to OKN-007, an investigational drug for the treatment of...
VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)
24 oct. 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
NX Development Corp. (NXDC) Launches FDA-Approved Gleolan™ (aminolevulinic acid HCl) for Enhanced Visualization of High-Grade Gliomas (including Glioblastomas)
03 oct. 2018 14h50 HE
|
NX Development Corp.
Lexington, KY, Oct. 03, 2018 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life sciences company, today announced the U.S. commercial launch of its flagship product Gleolan™ (aminolevulinic...